What Changes After HFpEF Is Confirmed?
Lisa Zahakos, RPA-C · Authorized synthetic narration

Now meet Angela. Her heart failure diagnosis has been confirmed.

Angela has confirmed heart failure with preserved ejection fraction. A diuretic helped her edema, but she still stops on the walk to her mailbox. She asks whether heart-failure medicines can help when she does not have diabetes.

Established diagnosis. heart failure with preserved ejection fraction confirmed after clinical and objective assessment; left ventricular ejection fraction 58 percent.

Current context. body mass index 35 kilograms per square meter; A one C 5.8 percent; no diabetes.

Safety starting point. E G F R 48 milliliters per minute per one point seven three square meters; potassium 4.6 milliequivalents per liter; review current volume status.

Patient goal. Walk to the mailbox with fewer stops; preserve strength and independence.

Match each treatment to the problem it is meant to solve.

Begin with current congestion, blood pressure, kidney function, rhythm, comorbidities, medication access and Angela’s goal. A drug that relieves fluid overload and a therapy that reduces future heart failure events may both have a role, but their purposes should be clear. Do not use improved edema as evidence that the overall risk has disappeared.

Contemporary heart failure with preserved ejection fraction care integrates heart failure-directed treatment with management of obesity, diabetes when present, hypertension, kidney disease, atrial fibrillation and coronary disease. The 2026 American College of Cardiology update incorporates newer evidence for S G L T 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists and incretin-based therapies within that broader approach. This is not a direction to give every agent to every patient in a fixed sequence.

Ask what Angela is already taking, what she has previously stopped and why. A medication list may contain an agent she never obtained or a dose she no longer uses. Explain the expected benefit in terms that match the evidence: symptoms, worsening heart failure events, hospitalization or another measured endpoint. Avoid promising an individual outcome from an average trial result.

S G L T 2 inhibition is not restricted to patients with diabetes.

In EMPEROR-Preserved, 5,988 participants with symptomatic heart failure and left ventricular ejection fraction above 40 percent received empagliflozin or placebo. The primary composite of cardiovascular death or heart failure hospitalization occurred in 13.8 percent versus 17.1 percent; the hazard ratio was 0.79 (95 percent confidence interval 0.69 to 0.90). The effect was largely driven by fewer heart failure hospitalizations and was observed with and without diabetes.

DELIVER tested dapagliflozin in 6,263 participants with left ventricular ejection fraction above 40 percent. Worsening heart failure or cardiovascular death occurred in 16.4 percent versus 19.5 percent, with a hazard ratio of 0.82 (95 percent confidence interval 0.73 to 0.92). The trials support heart failure treatment beyond glucose lowering. They do not show that one S G L T 2 inhibitor is superior to the other.

Angela’s absence of diabetes is therefore not a reason by itself to exclude an appropriate S G L T 2 inhibitor. Review the selected product’s heart failure indication, renal-use instructions, volume status, contraindications and access. Discuss genital infection symptoms, volume depletion and the possibility of ketoacidosis even without marked hyperglycemia. Provide individualized instructions for illness, fasting and procedures; empagliflozin’s label specifies withholding for at least three days before surgery or procedures associated with prolonged fasting, when possible.

Do not turn a monitoring conversation into a list the patient cannot use. Ask Angela which instruction she would follow if she were unable to eat or drink. Clarify whom she calls and when. Coordinate any diuretic adjustment with her volume assessment and the prescribing team rather than giving a universal instruction to reduce or stop it.

Here is the decision. Angela asks why a medicine commonly discussed for diabetes is being considered. Which answer is most accurate?

Pause here if you would like a moment to think it through.

The best next step in this case is: It is being considered for heart failure benefit; the evidence includes people without diabetes.

The indication and evidence should be explained in heart failure terms.

What the newer obesity trials actually establish.

STEP H F peff studied semaglutide 2.4 milligrams in 529 participants with obesity and heart failure with preserved ejection fraction without diabetes. At 52 weeks, the between-group improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score was 7.8 points, and weight reduction was greater with semaglutide. The main lesson is improvement in symptoms, physical limitations and weight in the studied population. It was not a mortality trial.

SUMMIT studied tirzepatide in 731 participants with obesity and left ventricular ejection fraction of at least 50 percent. Cardiovascular death or worsening heart failure occurred in 9.9 percent versus 15.3 percent (hazard ratio 0.62, 95 percent confidence interval 0.41 to 0.95). Fewer worsening heart failure events drove the result; cardiovascular death alone was not shown to be reduced.

These trials ask different questions and cannot be used as a head-to-head ranking. Their effect sizes use different endpoints, populations and follow-up. Weight loss, symptom improvement and clinical event reduction should not be collapsed into a single claim that all incretin therapies do the same thing.

Current US product indications also matter. The reviewed Wegovy and Zepbound labels contain obesity-related indications; the reviewed Zepbound label also includes obstructive sleep apnea in adults with obesity. Neither should be described here as carrying a specific heart failure with preserved ejection fraction indication. A clinician may use a medicine for an approved obesity indication in a patient who also has heart failure with preserved ejection fraction, while discussing heart failure with preserved ejection fraction trial evidence accurately. Verify the current exact label at prescribing and at course release.

What belongs in an individualized obesity conversation.

Ask permission to discuss weight and the symptoms that matter to Angela. Her goal is not simply a lower number: she wants to reach the mailbox and manage her daily responsibilities. Discuss treatment options in the context of access, preferences, other conditions and the ability to sustain nutrition and function.

Review the selected agent’s contraindications, precautions and interactions. For semaglutide and tirzepatide, the relevant labeling includes the medullary thyroid carcinoma/multiple endocrine neoplasia type 2 contraindication and important gastrointestinal, gallbladder, pancreatitis and other precautions. This case is not a dose-escalation protocol. Use the product-specific prescribing information and the patient’s clinical context.

Ask whether nausea, food insecurity, dental problems or living alone interfere with intake. A registered dietitian can help individualize nutrition while protecting function. Do not assign a universal protein, fluid or sodium prescription from this vignette; heart failure symptoms, kidney disease and nutritional status can change what is appropriate. Adapt physical activity to stability, symptoms and ability, and revisit strength and daily function as weight changes.

At follow-up, ask what was obtained, what was tolerated and what changed. Include symptoms and a functional goal alongside weight, blood pressure and laboratory findings. A change in weight could reflect fluid, nutritional intake or intentional loss; interpreting it requires context.

Read mineralocorticoid receptor antagonist evidence without assuming a class effect.

Mineralocorticoid receptor antagonists are not interchangeable evidence packages. Spironolactone and eplerenone are steroidal mineralocorticoid receptor antagonists; finerenone is nonsteroidal. Receptor selectivity and pharmacologic properties differ, but a mechanistic difference does not establish comparative clinical superiority.

In TOPCAT, spironolactone did not significantly reduce the overall primary composite endpoint in the studied heart failure with preserved ejection fraction population. heart failure hospitalization was lower, and hyperkalemia was more frequent. Important regional differences complicate interpretation. Selected patients may still have reasons for a steroidal mineralocorticoid receptor antagonist, but the result should not be described as an unequivocally positive overall heart failure with preserved ejection fraction trial.

In FINEARTS H F, 6,001 participants with left ventricular ejection fraction of at least 40 percent were randomized to finerenone or placebo. The composite rate of total worsening heart failure events and cardiovascular death was lower with finerenone (rate ratio 0.84, 95 percent confidence interval 0.74 to 0.95). Cardiovascular death alone was not significantly reduced. Hyperkalemia was more frequent. Its current heart failure indication and monitoring requirements are addressed in Teresa’s case.

Do not compare TOPCAT and FINEARTS H F as though patients were randomized between spironolactone and finerenone. Do not stack two mineralocorticoid receptor antagonists without a specific specialist-directed reason and a careful safety review. The treatment decision should identify the indication, the evidence and the monitoring burden.

Separate a pooled analysis from a heart failure with preserved ejection fraction trial.

FINE-HEART pooled participant-level data from FIDELIO D K D, FIGARO D K D and FINEARTS H F. Its 18,991 participants span chronic kidney disease with type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction. It is not a new head-to-head trial and is not a heart failure with preserved ejection fraction-only population. Its primary cardiovascular-death result did not reach statistical significance (hazard ratio 0.89, 95 percent confidence interval 0.78 to 1.01).

A 2026 sex analysis included 6,664 women, 35 percent of the pooled population. Women had a greater multimorbidity burden and were less likely to receive several commonly indicated CKM therapies at baseline. No evidence of treatment-effect heterogeneity by sex was found for the assessed finerenone outcomes. This supports attention to treatment access and equitable assessment; it does not establish a special female-only drug effect.

For Angela, close the treatment discussion by listing the clinical problem, the option chosen or deferred, the reason, the safety plan and her own goal. A defensible decision may include a reason not to use a therapy. Educational success is appropriate selection and follow-through, not the number of prescriptions or adoption of a particular brand.

Here is the decision. Angela reads that one trial improved symptoms and another reduced a composite event outcome. What should the clinician clarify?

Pause here if you would like a moment to think it through.

The best next step in this case is: Confirm each study’s population, endpoint and current product label before applying the result.

This avoids converting different evidence into an unsupported drug ranking.

The takeaway: Use heart failure evidence even without diabetes, distinguish symptom and event endpoints, and individualize obesity treatment. Compare each option with its own evidence and current label.

Before we move on, let’s apply that reasoning in more detail.

A treatment gap is a prompt to assess eligibility.

A US registry study published in 2025 examined 759,915 patients at 191 outpatient cardiovascular practices using records from July 2019 through June 2023. In the combined heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction group, recorded S G L T 2-inhibitor prescribing reached 12.8 percent in the final quarter. Female sex was associated with lower prescribing across the overall heart failure cohort. This is a historical observational finding, not a current 2026 rate or proof that every untreated patient should receive a medicine.

Use the gap to improve the decision process: confirm the syndrome, assess clinical and product-specific eligibility, explain the expected benefit and limits, review safety and cost, and document the agreed plan. A balanced education program measures the quality of those decisions. It does not set a target for prescriptions of a particular product or assume that education alone removes insurance, laboratory or referral barriers.

For heart failure, empagliflozin and dapagliflozin are each given at 10 milligrams daily when appropriate, but their renal-use instructions are not identical. Dapagliflozin initiation is not recommended below an E G F R of 25 milliliters per minute per one point seven three square meters; empagliflozin heart failure studies enrolled patients down to 20 and did not enroll those below 20. Review the current complete label and clinical context rather than applying a single class cutoff. Assess volume status and correct depletion before initiation; the loop-diuretic plan may need adjustment.

Review genital symptoms, serious urinary symptoms, poor intake and the possibility of ketoacidosis without marked hyperglycemia. Both labels direct withholding for at least three days before surgery or procedures associated with prolonged fasting, when possible. Restarting requires clinical stability and resumed oral intake. Give the patient an actionable instruction and a contact route rather than an unexplained list of adverse effects.

Separate guidance, approval and the woman in front of you.

Evidence evolves after a course is written. The 2026 European Society of Cardiology guideline adds contemporary European recommendations across ejection fraction categories and discusses obesity therapies in symptomatic heart failure. US indication, dosing and safety decisions still require the current US product label and applicable US guidance. A guideline recommendation and a regulatory indication answer different questions.

In the STEP H F peff pooled sex analysis, health-status improvement with semaglutide was similar in women and men, despite greater weight reduction in women. A women-focused case therefore does not justify claiming a uniquely larger heart failure treatment effect in women. Explain the population studied and the outcome measured, and avoid turning a subgroup description into a superiority claim.

Build an individualized plan that also addresses blood pressure, atrial fibrillation when present, kidney health, sleep-disordered breathing, physical function, nutrition and access. Diuretics treat congestion; disease-modifying treatment and comorbidity management have distinct purposes. Neither weight loss nor relief of edema is a reason to stop asking whether the complete heart failure plan is appropriate.